The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
The Combination of Low-dose Rituximab and All-trans Retinoic Acid as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial
Sponsor: Beijing Hospital
A PHASE2 clinical study on Immune Thrombocytopenia, this trial is ongoing. The trial is conducted by Beijing Hospital and has accumulated 10 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Nov 2019 — Feb 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Hospital
- Beijing Tongren Hospital
- Navy General Hospital, Beijing
- Peking University People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .